[1] J. Ambati, B. K. Ambati, S. H. Yoo, S. Ianchulev, and A. P. Ada- mis, “Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies,” Survey of Ophthalmology, vol. 48, no. 3, pp. 257–293, 2003.
[2] A. C. Bird, “Therapeutic targets in age-related macular disease,” The Journal of Clinical Investigation, vol. 120, no. 9, pp. 3033– 3041, 2010.
[3] J. Ambati and B. J. Fowler, “Mechanisms of age-related macular degeneration,” Neuron, vol. 75, no. 1, pp. 26–39, 2012.
[4] H. Kaneko, S. Dridi, V. Tarallo et al., “DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration,” Nature, vol. 471, no. 7338, pp. 325–332, 2011.
[5] P. T. V. M. de Jong, “Age-related macular degeneration,” The New England Journal of Medicine, vol. 355, no. 14, pp. 1474–1485, 2006.
[6] Q.-Y. Zhang, L.-J. Tie, S.-S. Wu et al., “Overweight, obesity, and risk of age-related macular degeneration,” Investigative Ophthal- mology and Visual Science, vol. 57, no. 3, pp. 1276–1283, 2016.
[7] A. Cougnard-Gre´goire, M.-N. Delyfer, J.-F. Korobelnik et al., “Long-term blood pressure and age-related macular degener- ation: the ALIENOR study,” Investigative Ophthalmology and Visual Science, vol. 54, no. 3, pp. 1905–1912, 2013.
[8] N. Joachim, P. Mitchell, G. Burlutsky, A. Kifley, and J. J. Wang, “The incidence and progression of age-related macular de- generation over 15 years: The Blue Mountains Eye Study,” Oph- thalmology, vol. 122, no. 12, pp. 2482–2489, 2015.
[9] K. Takayama, H. Kaneko, K. Kataoka et al., “Nuclear factor (erythroid-derived)-related factor 2-associated retinal pigment epithelial cell protection under blue light-induced oxidative stress,” Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 8694641,9 pages, 2016.
[10] T. Schick, L. Ersoy, Y. T. E. Lechanteur et al., “History of sunlight exposure is a risk factor for age-related macular degeneration,” Retina, vol. 36, no. 4, pp. 787–790, 2016.
[11] K. M. Bertram, C. J. Baglole, R. P. Phipps, and R. T. Libby, “Molecular regulation of cigarette smoke induced-oxidative stress in human retinal pigment epithelial cells: Implications for age-related macular degeneration,” American Journal of Physiology—Cell Physiology, vol. 297, no. 5, pp. C1200–C1210, 2009.
[12] H. Du, X. Xiao, T. Stiles, C. Douglas, D. Ho, and P. X. Shaw, “Novel mechanistic interplay between products of oxidative stress and components of the complement system in AMD pathogenesis,” Open Journal of Ophthalmology, vol. 6, no. 1, pp. 43–50, 2016.
[13] R. A. Armstrong and M. Mousavi, “Overview of risk factors for age-related macular degeneration (AMD),” Journal of Stem Cells, vol. 10, no. 3, pp. 171–191, 2015.
[14] R. Liu, T. Wang, B. Zhang et al., “Lutein and zeaxanthin supplementation and association with visual function in age- related macular degeneration,” Investigative Ophthalmology & Visual Science, vol. 56, no. 1, pp. 252–258, 2015.
[15] X. Wang, C. Jiang, Y. Zhang, Y. Gong, X. Chen, and M. Zhang, “Role of lutein supplementation in the management of age-rela- ted macular degeneration: meta-analysis of randomized con- trolled trials,” Ophthalmic Research, vol. 52, no. 4, pp. 198–205, 2014.
[16] J. Evans, “Antioxidant supplements to prevent or slow down the progression of AMD: a systematic review and meta-analysis,” Eye, vol. 22, no. 6, pp. 751–760, 2008.
[17] E. Y. Chew, T. E. Clemons, J. P. SanGiovanni et al., “Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression AREDS2 report no. 3,” JAMA Ophthalmology, vol. 132, no. 2, pp. 142–149, 2014.
[18] M. E. Aronow and E. Y. Chew, “Age-related eye disease study 2: perspectives, recommendations, and unanswered questions,” Current Opinion in Ophthalmology, vol. 25, no. 3, pp. 186–190, 2014.
[19] M. A. Brantley Jr., M. P. Osborn, B. J. Sanders et al., “The short- term effects of antioxidant and zinc supplements on oxidative stress biomarker levels in plasma: a pilot investigation,” Ameri- can Journal of Ophthalmology, vol. 153, no. 6, pp. 1104–1109, 2012.
[20] Y. F. Njie-Mbye, M. Kulkarni-Chitnis, C. A. Opere, A. Barrett, and S. E. Ohia, “Lipid peroxidation: pathophysiological and pharmacological implications in the eye,” Frontiers in Physiol- ogy, vol. 4, article no. 366, 2013.
[21] H. Esterbauer, R. J. Schaur, and H. Zollner, “Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes,” Free Radical Biology and Medicine, vol. 11, no. 1, pp. 81–128, 1991.
[22] H. Okuyama, T. Kobayashi, and S. Watanabe, “Dietary fatty acids—the N-6/N-3 balance and chronic elderly diseases. Excess linoleic acid and relative N-3 deficiency syndrome seen in Japan,” Progress in Lipid Research, vol. 35, no. 4, pp. 409–457, 1996.
[23] C. E. Ramsden, D. Zamora, B. Leelarthaepin et al., “Use of die- tary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis,” British Medical Journal, vol. 346, no. 7894, Article ID e8707, 2013.
[24] F. Schutt, M. Bergmann, F. G. Holz, and J. Kopitz, “Proteins modified by malondialdehyde, 4-hydroxynonenal, or advanced glycation end products in lipofuscin of human retinal pigment epithelium,” Investigative Ophthalmology and Visual Science, vol. 44, no. 8, pp. 3663–3668, 2003.
[25] D. Weismann, K. Hartvigsen, N. Lauer et al., “Complement factor H binds malondialdehyde epitopes and protects from oxidative stress,” Nature, vol. 478, no. 7367, pp. 76–81, 2011.
[26] D. Del Rio, A. J. Stewart, and N. Pellegrini, “A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress,” Nutrition, Metabolism & Cardiovas- cular Diseases, vol. 15, no. 4, pp. 316–328, 2005.
[27] X. L. Shen, L. H. Jia, P. Zhao et al., “Changes in blood oxidative and antioxidant parameters in a group of chinese patients with age-related macular degeneration,” Journal of Nutrition, Health & Aging, vol. 16, no. 3, pp. 201–204, 2012.
[28] Y. Totan, O. C¸ ekic¸, M. Borazan, E. Uz, S. So¨gu¨t, and O. Akyol, “Plasma malondialdehyde and nitric oxide levels in age related macular degeneration,” British Journal of Ophthalmology, vol. 85, no. 12, pp. 1426–1428, 2001.
[29] O¨ . Yildirim, N. A. Ate¸s, L. Tamer et al., “Changes in antioxidant enzyme activity and malondialdehyde level in patients with age- related macular degeneration,” Ophthalmologica, vol. 218, no. 3, pp. 202–206, 2004.
[30] M. Bergmann, F. Holz, and J. Kopitz, “Lysosomal stress and lipid peroxidation products induce VEGF-121 and VEGF-165 expression in ARPE-19 cells,” Graefe’s Archive for Clinical and Experimental Ophthalmology, vol. 249, no. 10, pp. 1477–1483, 2011.
[31] T. U. Krohne, N. K. Stratmann, J. Kopitz, and F. G. Holz, “Eff- ects of lipid peroxidation products on lipofuscinogenesis and autophagy in human retinal pigment epithelial cells,” Experi- mental Eye Research, vol. 90, no. 3, pp. 465–471, 2010.
[32] F. Ye, H. Kaneko, Y. Hayashi et al., “Malondialdehyde induces autophagy dysfunction and VEGF secretion in the retinal pigment epithelium in age-related macular degeneration,” Free Radical Biology and Medicine, vol. 94, pp. 121–134, 2016.
[33] H. M. Zajac¸-Pytrus, A. Pilecka, A. Turno-Krecicka, J. Adamiec- Mroczek, and M. Misiuk-Hojło, “The dry form of age-related macular degeneration (AMD): the current concepts of patho- genesis and prospects for treatment,” Advances in Clinical and Experimental Medicine, vol. 24, no. 6, pp. 1099–1104, 2015.
[34] M. A. Zarbin, R. P. Casaroli-Marano, and P. J. Rosenfeld, “Age- related macular degeneration: clinical findings, histopathology and imaging techniques,” Developments in Ophthalmology, vol. 53, pp. 1–32, 2014.
[35] K. Takayama, H. Kaneko, S. Ueno et al., “Evaluation of short- term outcomes of intravitreal aflibercept injections for age-rela- ted macular degeneration using focal macular electroretinogra- phy,” Retina, In press.
[36] K. Takayama, H. Kaneko, K. Kataoka et al., “Short-term focal macular electroretinogram of eyes treated by aflibercept & pho- todynamic therapy for polypoidal choroidal vasculopathy,” Gra- efe’s Archive for Clinical and Experimental Ophthalmology, 2016.
[37] K. Takayama, Y. Ito, H. Kaneko et al., “Cross-sectional pupillo- graphic evaluation of relative afferent pupillary defect in age- related macular degeneration,” Medicine, vol. 95, no. 39, Article ID e4978, 2016.
[38] F. G. Holz, J. S. Steinberg, A. Go¨bel, M. Fleckenstein, and S. Sch- mitz-Valckenberg, “Fundus autofluorescence imaging in dry AMD: 2014 jules gonin lecture of the retina research founda- tion,” Graefe’s Archive for Clinical and Experimental Ophthal- mology, vol. 253, no. 1, pp. 7–16, 2015.
[39] S. Schmitz-Valckenberg, F. G. Holz, A. C. Bird, and R. F. Spaide, “Fundus autofluorescence imaging: review and perspectives,” Retina, vol. 28, no. 3, pp. 385–409, 2008.
[40] P. Brzek, A. Ksiazek, L. Oldakowski, and M. Konarzewski, “High basal metabolic rate does not elevate oxidative stress during reproduction in laboratory mice,” Journal of Experimental Bio- logy, vol. 217, no. 9, pp. 1504–1509, 2014.
[41] S. Beatty, H.-H. Koh, M. Phil, D. Henson, and M. Boulton, “The role of oxidative stress in the pathogenesis of age-related macular degeneration,” Survey of Ophthalmology, vol. 45, no. 2, pp. 115–134, 2000.
[42] M. C. Marazita, A. Dugour, M. D. Marquioni-Ramella, J. M. Fig- ueroa, and A. M. Suburo, “Oxidative stress-induced premature senescence dysregulates VEGF and CFH expression in retinal pigment epithelial cells: implications for age-related macular degeneration,” Redox Biology, vol. 7, pp. 78–87, 2016.
[43] C. M. Spickett, “The lipid peroxidation product 4-hydroxy-2- nonenal: advances in chemistry and analysis,” Redox Biology, vol. 1, no. 1, pp. 145–152, 2013.
[44] Y. Li, X. Liu, T. Zhou et al., “Inhibition of APE1/Ref-1 redox activity rescues human retinal pigment epithelial cells from oxidative stress and reduces choroidal neovascularization,” Redox Biology, vol. 2, no. 1, pp. 485–494, 2014.
[45] X. Li, Y. Cai, Y.-S. Wang et al., “Hyperglycaemia exacerbates choroidal neovascularisation in mice via the oxidative stress- induced activation of STAT3 signalling in RPE cells,” PLoS ONE, vol. 7, no. 10, Article ID e47600, 2012.
[46] F. Ye, H. Kaneko, Y. Nagasaka et al., “Plasma-activated medium suppresses choroidal neovascularization in mice: a new thera- peutic concept for age-related macular degeneration,” Scientific Reports, vol. 5, article no. 7705, 2015.
[47] A. C. Bird, R. L. Phillips, and G. S. Hageman, “Geographic atro- phy: A histopathological assessment,” JAMA Ophthalmology, vol. 132, no. 3, pp. 338–345, 2014.
[48] I. Bhutto and G. Lutty, “Understanding age-related macular degeneration (AMD): relationships between the photorecep- tor/retinal pigment epithelium/Bruch’s membrane/choriocapi- llaris complex,” Molecular Aspects of Medicine, vol. 33, no. 4, pp. 295–317, 2012.
[49] J. Hanus, C. Anderson, and S. Wang, “RPE necroptosis in res- ponse to oxidative stress and in AMD,” Ageing Research Reviews, vol. 24, pp. 286–298, 2015.
[50] D. E. Bonds, M. Harrington, B. B. Worrall et al., “Effect of long- chain 𝜔-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes results of the age-related eye disease study 2 (AREDS2) randomized clinical trial,” JAMA Internal Medicine, vol. 174, no. 5, pp. 763–771, 2014.